EIC Transition Challenge: RNA-based therapies and diagnostics for complex or rare genetic diseases

The EIC Transition Challenge targets a broad range of applicants, from individual SMEs to research organizations and consortia, primarily within EU Member States and Associated Countries. The program's core objective is to advance RNA-based therapies and diagnostics, addressing unmet medical needs for complex or rare genetic diseases and driving their market readiness.

This funding program focuses on critical health innovations, specifically RNA-based therapies and diagnostics, supporting projects from the lab to relevant application environments. The scope covers technology maturation and business case development, ensuring readiness for clinical validation and commercialisation.

The EIC Transition Challenge provides grant funding for projects, with a specified range for financial support and a typical project duration, ensuring adequate time and resources for technology and business maturation.

Applicants must adhere to specific conditions regarding proposal submission, consortium composition, and intellectual property. Key regulatory documents and guidance are referenced to ensure compliance and successful project implementation.

The application process for the EIC Transition Challenge involves detailed submission requirements and a structured evaluation to identify high-potential projects. Support is available for applicants throughout these stages, and successful proposals may receive a Seal of Excellence.

The EIC Transition Challenge is governed by a comprehensive set of legal and official documents stemming from the broader Horizon Europe framework, ensuring transparent and legitimate operation.